Brief Title
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Official Title
A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Brief Summary
This research study is studying Daratumumab as a possible treatment for Waldenström
Macroglobulinemia.
Detailed Description
This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational drug to learn whether the drug works in treating a
specific disease. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved Daratumumab for this
specific disease but it has been approved for other uses.
Daratumumab is a monoclonal human antibody. An antibody recognizes a specific protein and
binds to it. Daratumumab binds to a protein called CD38 located on the surface of B cells
like WM. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38
on the cell surface when tested in laboratories.
In this research study, the investigators are evaluating the efficacy of Daratumumab as a
single agent in participants with WM that has come back or has shown no response to previous
treatment.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Overall Response Rate
Secondary Outcome
Progression Free Survival
Condition
Waldenström Macroglobulinemia
Intervention
Daratumumab
Study Arms / Comparison Groups
Daratumumab
Description: Daratumumab will be administered in three phases: Induction, consolidation and maintenance During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle During maintenance, daratumumab will be administered on day 1 of each 28-day cycle
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
13
Start Date
November 27, 2017
Completion Date
December 31, 2021
Primary Completion Date
January 31, 2021
Eligibility Criteria
Inclusion Criteria:
- Clinicopathological diagnosis of Waldenström Macroglobulinemia (Owen et al. 2003), and
meeting criteria for treatment using consensus panel criteria from the Second
International Workshop on Waldenström macroglobulinemia (Kyle et al. 2003)
- At least one previous treatment for WM with either documented disease progression or
no response (stable disease) to the most recent treatment regimen
- Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum
IgM level of >2 times the upper limit of normal of each institution is required
- Participants with symptomatic hyperviscosity or serum IgM >5,000 mg/dL to undergo
plasmapheresis prior to treatment initiation
- Age ≥18 years
- ECOG performance status ≤2 (see Appendix A)
- Participants must have preserved organ and marrow function as defined below:
- Absolute neutrophil count ≥ 1,000/mcL
- Platelets ≥ 50,000/mcL
- Hemoglobin ≥ 8 g/dL
- Total bilirubin ≤ 1.5 mg/dL or < 2 mg/dL if attributable to hepatic infiltration
by neoplastic disease
- AST/ALT ≤ 2.5 × institutional upper limit of normal
- EGFR ≥ 30 ml/min
- Not on any active therapy for other malignancies with the exception of topical
therapies for basal cell or squamous cell cancers of the skin.
- Females of childbearing potential (FCBP) must agree to use two reliable forms of
contraception simultaneously or have or will have complete abstinence from
heterosexual intercourse during the following time periods related to this study: 1)
while participating in the study; and 2) for at least 90 days after discontinuation
from the study. Men must agree to use a latex condom during sexual contact with a FCBP
even if they have had a successful vasectomy. FCBP must be referred to a qualified
provider of contraceptive methods if needed. FCBP must have a negative serum pregnancy
test at screening.
- Able to adhere to the study visit schedule and other protocol requirements.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Any serious medical condition, laboratory abnormality, uncontrolled intercurrent
illness, or psychiatric illness/social condition that would prevent study
participation.
- Concurrent use of any other anti-cancer agents or treatments or any other
investigational agents.
- Any condition, including the presence of laboratory abnormalities, which places the
participant at unacceptable risk if he/she were to participate in the study or
confounds the ability to interpret data from the study.
- Known CNS lymphoma.
- New York Heart Association classification III or IV heart failure.
- Known history of Human Immunodeficiency Virus (HIV), active infection with Hepatitis B
Virus (HBV), and/or Hepatitis C Virus (HCV).
- Lactating or pregnant women.
- Grade >2 toxicity (other than alopecia) continuing from prior anti-cancer therapy.
- History of non-compliance to medical regimens.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Jorge J Castillo, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT03187262
Organization ID
17-164
Responsible Party
Principal Investigator
Study Sponsor
Dana-Farber Cancer Institute
Collaborators
Janssen, LP
Study Sponsor
Jorge J Castillo, MD, Principal Investigator, Dana-Farber Cancer Institute
Verification Date
November 2022